FDA approves tuberculosis drug that works on hard-to-treat cases

For the tens of thousands of people around the world who become infected with an extensively drug-resistant form of TB each year, pretomanid “could be a major breakthrough,” said Matthew Kavanagh, a health policy expert at Georgetown.

“It shifts XDR-TB from most likely a death sentence to likely survivable with effective treatment,” he said.

Read the article here.